Methicillin-resistant Staphylococcus Aureus Drugs Market - By Drug Class (Glycopeptides), MRSA Type (Hospital-acquired, Community-acquired), Route of Administration, Indication (Bacteraemia), Distribution Channel - Global Forecast (2024

Description

Global Methicillin-resistant Staphylococcus Aureus Drugs Market size will witness 4.2% CAGR between 2024 and 2032 owing to ongoing challenges, triggered by antibiotic-induced Staphylococcus aureus strains. Conventional antibiotics against methicillin-resistant staphylococcus aureus MRSA are ineffective, and new treatment options are critically needed.

Pharmaceutical companies, research institutes, and government agencies are also intensifying their efforts to develop new drugs, vaccines, and therapeutic strategies to combat MRSA infections. For instance, in December 2023, scientists discovered a new class of antibiotics for drug-resistant Staphylococcus aureus bacteria from the utilization of more transparent deep learning models. Advances in genomics, immunology, and drug discovery mechanisms are also providing new insights into the pathogenesis of MRSA infections and potential therapeutic targets for emphasizing the importance of emergency medicine. This increased focus on R&D is poised to drive innovations and shape the future of MRSA treatments.

The overall industry is classified into drug class, MRSA type, route of administration, indication, distribution channel and region.

According to drug class, the methicillin-resistant staphylococcus aureus drugs industry from the lipopeptides segment will undergo rigorous development from 2024 to 2032. Lipopeptides are promising antimicrobial agents, known for their potent activity against MRSA and other drug-resistant bacteria. As MRSA strains are poorly responsive to conventional antibiotics, lipopeptides offer valuable alternatives due to their unique mechanism of action and low resistance. Several pharmaceutical companies are also focusing on developing and marketing lipopeptide-based drugs to combat the growing threat of MRSA infections.

On the basis of MRSA type, the methicillin-resistant staphylococcus aureus drugs market from the community acquired CA-MRSA segment will register notable CAGR from 2024 to 2032. This is due to the rise in CA-MRSA infections, which pose a serious public health concern. The ability of CA-MRSA strains to cause serious infections in otherwise healthy individuals, has led to the increasing demand for effective treatment. Pharmaceutical companies are also focusing on drugs targeting CA-MRSA strains to combat this growing threat.

Europe methicillin-resistant staphylococcus aureus drugs market will showcase a commendable CAGR from 2024 to 2032 due to the increasing need for effective treatments. With the increasing incidence of healthcare-associated and community-acquired MRSA infections, new antibiotics are urgently required in the region. Pharmaceutical companies are also investing in R&D activities to meet this demand while introducing new drugs to combat the prevalence of MRSA strains in Europe.

Product Code: 9303

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of MRSA infections
  - 3.2.1.2 Growing antibiotic resistance
  - 3.2.1.3 Advancements in drug development
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of therapeutics
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Glycopeptides
5.3 Lipopeptides
5.4 Oxazolidinones
5.5 Cephalosporin
5.6 Tetracycline
5.7 Folate antagonist
5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By MRSA Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospital-acquired (HA-MRSA)
6.3 Community-acquired (CA-MRSA)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Skin and soft tissue infections
8.3 Bone & joint infections
8.4 Respiratory infections
8.5 Bacteremia
8.6 Other indications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

11.1 AbbVie Inc.
11.2 Basilea Pharmaceutica Ltd
11.3 Baxter International Inc.
11.4 Cumberland Pharmaceuticals Inc.
11.5 GlaxoSmithKline plc.
11.6 Johnson & Johnson
11.7 Merck & Co., Inc.
11.8 Novartis AG
11.9 Pfizer Inc.
11.10 Teva Pharmaceutical Industries Ltd.

Methicillin-resistant Staphylococcus Aureus Drugs Market - By Drug Class (Glycopeptides), MRSA Type (Hospital-acquired, Community-acquired), Route of Administration, Indication (Bacteraemia), Distribution Channel - Global Forecast (2024 - 2032)